We are in exciting times for gene therapy for both neuro degeneration and rare neurological diseases, with advances in both fields signaling new opportunities in neuro degeneration and new therapies for rare diseases already reaching patients; often driving by patient led innovation and collaborative co-development. Investor and industry interest is growing, yet challenges remain that can only be addressed by bringing together the leading translational research, clinicians, patients, entrepreneurs, CEOs and other executives from the leading companies, with relevant therapeutic area and business development heads from big pharma and large biotech,as well as CROs, CMOs and other Partners and Directors heading neuroscience investment at the most active and important investment funds.